Smad3 Mediates Angiotensin II– and TGF-β1–Induced Vascular Fibrosis
- 28 April 2006
- journal article
- editorial
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 98 (8) , 988-989
- https://doi.org/10.1161/01.res.0000221824.87718.c0
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Essential Role of Smad3 in Angiotensin II–Induced Vascular FibrosisCirculation Research, 2006
- Angiotensin II Activates the Smad Pathway in Vascular Smooth Muscle Cells by a Transforming Growth Factor-β–Independent MechanismCirculation, 2005
- Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus AtenololHypertension, 2005
- Transforming Growth Factor β Receptor Endoglin Is Expressed in Cardiac Fibroblasts and Modulates Profibrogenic Actions of Angiotensin IICirculation Research, 2004
- Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) studyExpert Opinion on Pharmacotherapy, 2004
- Smad Expression in Human Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertensionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- TGF-?1 and angiotensin networking in cardiac remodelingCardiovascular Research, 2004
- Wounding SmadNature Cell Biology, 1999
- Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory responseNature Cell Biology, 1999